Glycomine has raised $115 million in a Series C round to advance its rare disease drug GLM101 into deeper clinical testing. The funding will support development for the treatment of PMM2-CDG, a genetic disorder affecting thousands of patients.

Apr 16, 2025•8 months ago

Amount Raised

$115 Million

Round Type

series c

San Carlos

Description

Glycomine, a biotechnology startup, has raised a $115 million Series C round to push its lead program deeper into clinical testing. The funding will support the development of its therapy GLM101, designed to treat PMM2-CDG, a rare genetic disorder. This funding is critical as there are no approved treatments for the condition, which affects a significant number of individuals in the U.S. and Europe

Glycomine has raised $115 million in a Series C round to advance its rare disease drug GLM101 into deeper clinical testing. The funding will support development for the treatment of PMM2-CDG, a genetic disorder affecting thousands of patients.

Description

Company Information

Related People

Funding Insights

Glycomine has raised $115 million in a Series C round to advance its rare disease drug GLM101 into deeper clinical testing. The funding will support development for the treatment of PMM2-CDG, a genetic disorder affecting thousands of patients.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information